Endpoints News Names Mirador Therapeutics a 2024 “Endpoints 11” Winner

SAN DIEGO, September 27, 2024 – Mirador Therapeutics, Inc., a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I), today announced that Endpoints News has named Mirador to its 2024 “Endpoints 11” list of the most promising startups in the biopharmaceutical industry. The annual honor recognizes private companies that are pursuing the most ambitious scientific breakthroughs of tomorrow, backed by expert leadership and strong investor confidence.

“Endpoints 11 is one of the most distinguished accolades a young company can receive, and we thank the Endpoints editorial team for recognizing our potential as a leader in next-generation precision medicine for I&I,” said Mark C. McKenna, Chairman and CEO of Mirador. “The millions of patients suffering from immune-mediated inflammatory and fibrotic diseases inspire our bold vision to accelerate a new era of precision immunology to deliver transformational therapeutics with potential to significantly improve lives. I am proud of the unrelenting focus and strategic acumen our team has shown since we launched earlier this year. Supported by our exceptional board of directors and investors, we are making significant progress with our diversified, high-value portfolio.”

Endpoints announced and celebrated the 2024 Endpoints 11 winners at an awards gala held in Boston on Thursday, September 26, 2024, as well as featured this year’s winners on the outlet’s website.

About Endpoints

Endpoints News is biopharma’s trusted news authority, read by thousands of innovative biotechs and leading pharmaceutical companies. As part of the Financial Times’ FT Specialist group, Endpoints publishes daily newsletters, delivers top-tier reporting on its website, hosts industry-leading events and builds products connecting and informing sophisticated business audiences. For more information, visit www.endpts.com.

About Mirador Therapeutics

Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in-class precision medicines for immunology and inflammation. Mirador aims to revolutionize precision medicine with its proprietary Mirador360^TM development engine that leverages cutting-edge biology, multi-modal data and advanced analytics to rapidly advance new medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA. For more information, please visit us at www.miradortx.com and follow us on LinkedIn.